Table 1. Demographic details of post-mortem midbrain mRNA and protein cohorts.

Demographic	mRNA cohort			Protein cohort
	Control mRNA (n=29)	Schizophrenia mRNA (n=28)	Statistics mRNA	Control protein (n=27)	Schizophrenia protein (n=26)	Statistics protein
Age (years)	51.2 (22–69)	51.4 (26–67)	P=0.10, df=55, t=−0.06	52.21 (22–69)	52.29 (26–67)	P=0.82, df=52, t=−0.23
Gender (M, F)	(20, 9)	(19, 9)	—	(19, 8)	(16, 10)	—
pH	6.67±0.26	6.51±0.20*	P=0.01, df=55, t=2.6	6.69±0.24	6.51±0.23*	P=0.01, df=52, t=2.6
PMI (h)	31.9±10.12 (15–50)	35.7±17.71 (5–72)	P=0.33, df=55, t=−0.98	32.75±9.90 (15–50)	38.21±18.20 (5–72)	P=0.17, df=52, t=−1.38
RIN	5.6±1.14	5.6±1.31	P=0.95, df=55, t=−0.06	na	na	na
Duration of illness (year)	na	28.31±12.72 (4–49) (28.19–39)	—	na	29.12±13.02 (4–49) (30, 19.3–39)	—
Daily chlorpromazine equivalent dose (mg)	na	736.45±520.50 (n=22) (583.0, 387.5–825.0)	—	na	716.37±557.76 (n=19) (553.0, 350.0–784.0)	—
Last-recorded chlorpromazine equivalent dose (mg)	na	597.54±497.64 (n=28) (462.5, 192.5–927.0)	—	na	616.20±506.60 (n=26) (475.0, 250.0–1025.0)	—
Life time chlorpromazine equivalent dose (g)	na	8231.44±8714.24 (n=22) (4726.8, 3442.0–8563.0)	—	na	8427.92±9348.47 (n=19) (4471.3, 3036.8–8212.5)	—
Depression symptoms over lifetime (yes, no, unknown)	1 (SSRI), 26, 2	8 (6 on SSRIs, 2 on TCAs), 19, 1	—	1 (SSRI), 24, 2	7 (5 on SSRIs, 2 on TCAs), 18, 1	—
Symptoms (mostly positive, mostly negative, unknown)	na	18, 7, 3	—	na	19, 7, 0	—
Agonal state (optimal/good/poor/unknown)	18/10/0/1	17/9/0/2	—	17/10/0/0	15/10/0/1	—
Smoker at time of death (yes/no/unknown)	11/12/6	16/6/6	—	11/11/5	16/6/4	—

Abbreviations: F, female; M, male; na, not applicable; PMI, post-mortem interval; RIN, RNA integrity; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

Data are mean±s.d. (range) (median, interquartile range). *P⩽0.05.